about
HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interactionComparative analysis of NRF2-responsive gene expression in AcPC-1 pancreatic cancer cell lineBRCA1 and Oxidative StressInhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabineCombination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells.β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells.Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6Loss of BRCA1 leads to an increased sensitivity to Bisphenol A.Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells.Novel carbazole inhibits phospho-STAT3 through induction of protein-tyrosine phosphatase PTPN6.Correlations between BRCA1 defect and environmental factors in the risk of breast cancer.Disruption of STAT3-DNMT1 interaction by SH-I-14 induces re-expression of tumor suppressor genes and inhibits growth of triple-negative breast tumor.Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.Application of a non-hazardous vital dye for cell counting with automated cell counters.Ni/NiO core/shell nanoparticles for selective binding and magnetic separation of histidine-tagged proteins.Exosomes derived from human adipose tissue-derived mesenchymal stem cells alleviate atopic dermatitis.Exosomes from Human Adipose Tissue-Derived Mesenchymal Stem Cells Promote Epidermal Barrier Repair by Inducing de Novo Synthesis of Ceramides in Atopic DermatitisAdvances in Analysis of Biodistribution of Exosomes by Molecular ImagingMesenchymal Stem/Stromal Cell-Derived Exosomes for Immunomodulatory Therapeutics and Skin Regeneration
P50
Q28383407-44131E5F-5415-45C1-A468-B857957E859DQ28384407-1351060A-B9CE-4B97-BAF4-E945ACE82EB7Q28388921-29C185D9-3777-4685-9FD5-4CC3F5036553Q28396251-C7F7966F-CDF4-4A45-A548-63D708C5E799Q33778101-3A8FD8F4-52C6-40F8-A63B-C75488F6FBD1Q35137658-6A4DD794-8EBC-48DC-80CE-0A7722EE2E99Q35625440-0DCD6FA5-D8F9-491F-9C62-B9674A9DE424Q36422318-EA0B6C72-4463-4978-8A2B-C99A6A83C412Q37294562-5FE0A8DD-7175-4CF1-A91F-99B74CA0473FQ38979718-12963BCD-3EEA-467E-A504-888CD090B32BQ39153226-724196E0-C0D9-46AF-94A0-552132251559Q47117432-342ADCB3-9792-463C-ACA5-9E6EA91CB8D2Q48533012-EB56B004-A8C8-4B6C-B1C2-6042846B2406Q50209464-11AB9023-5CF3-40FE-A60E-40D581463115Q51145622-BC08326F-F867-49AD-A974-F309968B5CA1Q55645378-6AA186FA-9BFB-47FB-8C07-F27BE27AFE40Q90271409-927B1838-6575-4D52-9F95-756DDA98E12CQ92816008-168E272D-AC56-4BEB-BD44-01F6C71675EEQ94557298-04A58730-444B-46EC-A195-A260E0B58B13
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Yong-Weon Yi
@en
Yong-Weon Yi
@nl
type
label
Yong-Weon Yi
@en
Yong-Weon Yi
@nl
prefLabel
Yong-Weon Yi
@en
Yong-Weon Yi
@nl
P31
P496
0000-0001-6895-0465